All In MedTech

Device Trial Radar · NCT07031492

Relieving Carb Counting Via Flexible-userinteraction Multiple-input Control Architectures

Beyond Hybrid Artificial Pancreas Systems: Relieving Carb Counting Via Flexible-userinteraction Multiple-input Control Architectures

Last checked: Nov 19, 2026Latest source record: Jun 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

10

Planned (sponsor's estimate)

Start

Sep 2025

Primary completion

Dec 2025

Study completion Dec 2025

Sponsor

Sponsor type
Academic, hospital or other
Collaborators
Universitat Politècnica de València
First posted
Jun 22, 2025

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Developing algorithms for Automated Insulin Delivery (AID) systems that alleviate the burden of meal announcements, culminating in the FLEX-AP system. This fully automated artificial pancreas system is designed to operate without meal or exercise announcements while allowing for optional user input. FLEX-APaims to achieve a balance between glycemic control and user quality of life by incorporating user preferences into its operation. The FLEX-AP system features a flexible control architecture tailored to handle unannounced meals and exercise. It also allows for optional meal announcements and offers guidance for mitigating hypoglycemia, such as counterregulatory actions like rescue carbohydrate intake for patients who prefer it. The proposed benefit of FLEX-AP is to improve glycemic control while respecting individual preferences, which sets it apart from existing AID systems.

Conditions

  • T1DM - Type 1 Diabetes Mellitus

Interventions

  • FLEX-AP system will be implemented to T1D patientsDevice

    A FLEX-AP system will be implemented to T1D patients after they have been given a Minimed 780G hybrid closed-loop system

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Efficacy of the FLEX-AP systemTime frame: 4 weeks
  2. Safety of the FLEX-AP systemTime frame: 4 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hospital Universitario Ramón y Cajal

    Madrid, Madrid, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.